BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

Biotechnology

Healthcare
$61.43 -0.18%

-$0.10 today

Market cap
$11.90B
Beta
0.24
P/E (TTM)
39.4
EPS (TTM)
$1.40
52W Low $49.26High $66.28

Volume 3.07M

Average 2.04M

BMRN Other Non-Cash Items

Other non-cash adjustments that reconcile net income to operating cash flow.

BioMarin Pharmaceutical Inc.NASDAQ: BMRN

Other Non-Cash Items · Q3 FY2026 · quarter ended Sep 2026

Other non-cash items grows, but more slowly than its trailing trend

Q3 FY2026 other non-cash items of $159.79B rose 70479.7% year over year, behind the +261755.8% change in trailing-twelve-month other non-cash items. Sequentially, it rose 1405880.4% from the prior quarter.

Context

  • Other non-cash items amounted to 8.6% of revenue in FY2025, up 8.3 pp from a year earlier.
  • Other non-cash items increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +70479.7% toward the trailing-twelve-month pace of +261755.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$159.79B+1405880.4% QoQ
Last fiscal yearDec 2025
$278.07M+3256.3% YoY
LTMSep 2026
$159.68B+261755.8% YoY
Other Non-Cash Items past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+70479.7%——
1 year+3256.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Non-Cash Items history

USD · from the cash flow

Latest · FY2025
278.07M USD
Year-over-year change
+3256.3%
4-year CAGR
+115.5%

Other Non-Cash Items vs competitors

How BMRN compares with its peers on the latest reported figures

  • Peers report in different currencies, so other non-cash items is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +261755.8% is the highest of 11, against a peer median of -32.8%.
  • Other non-cash items amounts to 15.5% of revenue for BMRN, versus a peer median of 3.9%.
BMRN Competitors
Other Non-Cash Items for BMRN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$159.68B USD+261755.8%—15.5%
ASNDAscendis Pharma A/SLTM Sep 2026€432.34M EUR-272011.5%+144.7%35.8%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026$232.41M USD+160.5%—32.6%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$121.03M USD+1589.7%—18.6%
INSMInsmed IncorporatedLTM Jun 2026$71.1M USD-18.5%+238.8%6.3%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$37.79M USD-205.6%—3.7%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$26.69M USD-47.0%—4.0%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$26.06M USD-119.7%-10.2%0.5%
VRTXVertex Pharmaceuticals IncorporatedLTM Jun 2026$14.6M USD-102.9%+68.2%0.1%
PHARPharming Group N.V.LTM Mar 2026$14.12M USD+410.1%—3.8%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$1.65M USD+102.2%—0.2%
Peer median (excluding BMRN) —-32.8%+106.5%3.9%

Competitors are the stored peer set for BMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(64.08M)141.56M167.65M426.86M348.9M
Depreciation & Amortization108.04M101.97M104.39M96.43M79.56M
Deferred Income Tax(15.61M)(52.09M)(44.98M)56.1M48.74M
Stock-Based Compensation197.26M196.31M207.1M201.57M181.41M
Change in Working Capital66.03M(96.38M)(336.54M)(216.4M)(108.68M)
Accounts Receivables65.57M(82.03M)(190.44M)(57.91M)(228.05M)
Inventory(35.06M)(68.26M)(157.06M)(63.53M)119.21M
Accounts Payables15.69M59.02M68.85M(32.24M)66.14M
Other Working Capital19.83M(5.1M)(57.9M)(62.72M)(65.97M)
Other Non-Cash Items12.89M(115.47M)61.65M8.29M278.07M
Operating Cash Flow304.54M175.9M159.26M572.84M827.99M
Capital Expenditures(119.23M)(120.96M)(107.61M)(97.42M)(103.04M)
Acquisitions (Net)0000(285.19M)
Purchases of Investments(937.14M)(611.81M)(868.5M)(410.25M)(355.88M)
Sales of Investments691.05M620M864.86M633.02M337.8M
Other Investing Activities(24.64M)103.33M(10.92M)(853K)(7.94M)
Investing Cash Flow(366.31M)(20.03M)(111.24M)136.49M(414.24M)
Debt Repayment(3.04M)(2.61M)(2.29M)(494.99M)0
Common Stock Issued069.33M69.35M014.46M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.99M(85.38M)(85.79M)(31.46M)(56.85M)
Financing Cash Flow(48K)(18.65M)(18.73M)(526.45M)(42.39M)
Effect of Forex Changes(57K)32K1.31M4.83M(2.52M)
Net Change in Cash(61.88M)137.26M30.6M187.72M368.84M
Free Cash Flow185.31M54.94M51.65M475.42M724.96M

BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

Intrinsic Alpha fair value

Locked

Current Price

$61.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.